Agreement to produce similar biotherapeutic product in Turkey

Home/Pharma News | Posted 05/11/2021 post-comment0 Post your comment

On 22 October 2021, an important agreement was signed between Nobel Pharmaceuticals and the IBG-OzBio partnership for the manufacturing of a similar biotherapeutic product in Turkey. This hopes to be a springboard for further collaborations and medicinal product development in the country. 

12 AA010179

The similar biotherapeutic product is used to treat a rare disease and has been jointly developed by IBG and OzBio and will now be manufactured by Nobel in Turkey.

The Scientific and Technological Research Council of Turkey (TÜBİTAK) has stepped in to facilitate the production of the similar biotherapeutic product in Turkey. This requires import of the cell clone that produces the similar biotherapeutic product which was developed jointly by Turkey-based IBG and US-based OzBio. Following this, Turkey-based Nobel will lead the development of the similar biotherapeutic product within the country.

This is part of TÜBİTAK’s ‘cooperation before competition’ initiative which, in this case, hopes to bring the four organizations together to successfully develop, trial and launch the similar biotherapeutic product. This is a pivotal point for drug development in Turkey. It hopes to decrease the countries dependency on drug imports and help Turkey become a country that designs, develops and produces medicines and healthcare technology.

Related articles
CinnaGen to invest in Turkish pharmaceuticals sector

Dr Reddy’s and TRPharm collaborate on biosimilars in Turkey

Merck Millipore to collaborate with Turkish firm on biosimilars


The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish.

View last week’s headline article: Los datos apoyan la intercambiabilidad de los biosimilares de la UE

Browse the news in the Latin American Forum!

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.


Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.

Vea el artículo principal de la semana pasada: Los datos apoyan la intercambiabilidad de los biosimilares de la UE

Explore las noticias en el Foro Latinoamericano!

Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa. 


Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2021 Pro Pharma Communications International. All Rights Reserved.

comment icon Comments (0)
Post your comment
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010